Search

GENESIS Biomed directly invested €50,000 in Corify Care in this round as a sign of commitment to the project. This is the 21st round of funding that the consultancy has helped to close since its

Study led by Medical College of Wisconsin and exploring the combination with azacitidine.

Dr. Beaurang has over 25 years of experience in biotechnology focusing on corporate strategy, business development, oncology, immunology and neurology.

This report aims to provide an overview of the most promising emerging developments to serve as a reference for Europe's priorities and align with the EU's innovation policy.

Interview Francisco Fernández-Avilés – Professor of Cardiovascular Medicine at the UCM and Co-Founder of Corify Care.

We interviewed Lidya Domínguez, Director of Clinical Research at Sermes CRO, experts in European clinical trial regulation and CTIS, who have been involved in its development since 2017 as members of

Out of the 930 studies authorized by the AEMPS last year, a total of 52 focused on advanced therapy medicines.

"2025 is a turning point for Almirall as we are entering an era of sustained double-digit growth of our net sales CAGR to 2030, and increased EBITDA margins to around 25% by 2028," stated Carlos

Although respiratory diseases are generally not severe, they cause thousands of hospitalizations and deaths worldwide every year, which would increase dramatically if surveillance systems were not in

Study conducted under the CRADA agreement between NCI and Oryzon.

The medical costs of Alzheimer's disease in hospital care increased during the study period, with an average annual cost per patient of 4,969 euros.

Among these, the following stand out 8º Sachs Annual Neuroscience Innovation Forum, 14º Annual LifeSci Advisors Corporate Access Event, Invest Securities BioMed Forum 2025, MidCap Event Frankfurt 2025

Meet Grupo AIA, our new member. We spoke with Guillermo Rodriguez Lázaro, Chief Scientific Director.

In Spain, the incidence of sepsis is 212 cases per 100,000 inhabitants per year, with a mortality rate ranging from 15% to 50%, depending on the severity and speed of treatment.